Showing results (71-80 of 292) with videos related to
Sort By:
Pageof 30
Orphanet Journal of Rare Diseases|September 12, 2014
Reimbursement of orphan drugs in Belgium: what (else) matters?Eline Picavet, David Cassiman, Steven SimoensHealth Policy (Amsterdam, Netherlands)|September 20, 2012
Evaluating and improving orphan drug regulations in Europe: a Delphi policy studyEline Picavet, David Cassiman, Steven SimoensPharmacy Practice|September 24, 2014
Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycinSteven Simoens, Nik De Corte, Gert LaekemanHuman Resources for Health|July 20, 2004
Impact, regulation and health policy implications of physician migration in OECD countriesMélanie Bourassa Forcier, Steven Simoens, Antonio GiuffridaAmerican Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 11, 2008
Economic effects of clinical pharmacy interventions: a literature reviewThomas De Rijdt, Ludo Willems, Steven SimoensCNS Drugs|March 29, 2012
Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in BelgiumSteven Simoens, Liesbet De Naeyer, Peter DedekenFrontiers in Pharmacology|June 6, 2022
Critical Reflections on Reimbursement and Access of Advanced TherapiesSteven Simoens, Katrien De Groote, Cornelis BoersmaExpert Review of Pharmacoeconomics & Outcomes Research|April 25, 2014
Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainabilityPieter Dylst, Arnold G Vulto, Steven SimoensPharmaceuticals (Basel, Switzerland)|June 2, 2021
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case StudySteven Simoens, Arnold G Vulto, Pieter DylstFrontiers in Pharmacology|October 21, 2011
Valorising and creating access to innovative medicines in the European unionLieven Annemans, Irina Cleemput, Frank Hulstaert, et al.Pageof 30